Dose-dependent improvement of myoclonic hyperkinesia due to valproic acid in eight Huntington's Disease patients: A case series

BMC Neurology

Volumn 6, Issue , 2006, Pages

  Saft, Carsten ^a   Lauter, Thorsten ^a   Kraus, Peter H ^a   Przuntek, Horst ^a   Andrich, Juergen E ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CLONAZEPAM; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; ETIRACETAM; HALOPERIDOL; LORAZEPAM; MELPERONE; OXAZEPAM; QUETIAPINE; RILUZOLE; SULPIRIDE; TETRABENAZINE; TIAPRIDE; VALPROIC ACID; ANTICONVULSIVE AGENT;

ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG RESPONSE; FEMALE; HUMAN; HUNTINGTON CHOREA; HYPERKINESIA; MALE; MYOCLONUS; RATING SCALE; SCORING SYSTEM; SYMPTOM; TREATMENT OUTCOME; TREATMENT RESPONSE; VIDEORECORDING; ADULT; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

ADULT; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HUNTINGTON DISEASE; HYPERKINESIS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VALPROIC ACID;

EID: 33645216173     PISSN: 14712377     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-6-11     Document Type: Article

References (36)

1. Aoba S, Komiyama A, Yamada H, Hasegawa O: Action myoclonus in adult Huntington's disease. Rinsho Shinkeigaku 1992, 32:739-42.
2. Previdi P, Borgonovi R: Myoclonus and Huntington's chorea: description of a case. Ital J Neurol Sci 1980, 1:189-91.
3. Siesling S, Vegter-van der Vlis M, Roos RA: Juvenile Huntington disease in the Netherlands. Pediatr Neurol 1997, 17:37-43.
4. Bachman DS, Butler IJ, McKhann GM: Long-term treatment of juvenile Huntington's chorea with dipropylacetic acid. Neurology 1977, 27:193-7.
5. Gram L, Bentsen KD: Valproate: an updated review. Acta Neurol Scand 1985, 72:129-39.
6. Lenman JA, Ferguson IT, Fleming AM, Hemberg M, Robb JE, Turnbull MJ: Sodium valproate in chorea. Br Med J 1976, 6:1107-8.
7. Pearce I, Heathfield KW, Pearce MJ: Valproate sodium in Huntington chorea. Arch Neural 1977, 34:308-9.
8. Shoulson I, Kartzinel R, Chase TN: Huntington's disease: treatment with dipropylacetic acid and gamma-aminobutyric acid. Neurology 1976, 26:61-3.
9. Symington GR, Leonard DP, Shannon PJ, Vajda FJ: Sodium valproate in Huntington's disease. Am J Psychiatry 1978, 135:352-4.
10. Tan BK, Leijnse-Ybema HJ, Zee MF: Sodium valproate in Huntington's chorea. Clin Neural Neurosurg 1976, 79:62-5.
11. Carelia F, Scaioli V, Ciano C, Binelli S, Oliva D, Girotti F: Adult onset myoclonic Huntington's disease. Mov Disord 1993, 8:201-5.
12. Vogel CM, Drury I, Terry LC, Young AB. Myoclonus in adult Huntington's disease. Ann Neurol 1991, 29:213-5.
13. Thompson PD, Bhatia KP, Brown P, Davis MB, Pires M, Quinn NP, Luthert P, Honovar M, O'Brien MD, Marsden CD, Harding AE: Cortical myoclonus in Huntington's disease. Mov Disord 1994, 9:633-41.
14. Kereshi S, Schlagenhauff RE, Richardson KS: Myoclonic and major seizures in early adult Huntington's chorea: case-report and electro-clinical findings. Clin Electroencephalogr 1980, 11:44-7.
15. Novom S, Danna S, Goldberg MA: Intention myoclonus in Huntington's disease. Bug Los Angeles Neural Soc 1976, 41:82-4.
16. Funakawa I, Kimura K, Jinnai K: Cortical reflex myoclonus in adult onset Huntington's disease. Rinsho Shinkeigaku 2004, 44:639-42.
17. Grove VE Jr, Quintanilla J, DeVaney GT: Improvement of Huntington's disease with olanzapine and valproate. N Engl J Med 2000, 343:973-4.
18. Huntington Study Group: Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996, 11:136-42.
19. Siesling S, van Vugt JP, Zwinderman KA, Kieburtz K, Roos RA: Unified Huntington's disease rating scale: a follow up. Mov Disord 1998, 13:915-9.
20. Saft C, Andrich J, Meisel NM, Przuntek H, Muller T: Assessment of complex movements reflects dysfunction in Huntington's disease. J Neurol 2003, 250:1469-74.
21. Saft C, Andrich J, Meisel NM, Przuntek H, Muller T: Congruent deterioration of complex and simple movements in patients with Huntington's disease. J Neural Transm Suppl 2004, 68:97-104.
22. Paulsen JS, Zhao H, Stout JC, Brinkman RP, Guttman M, Ross CA, et al: Clinical markers of early disease in persons near onset of Huntington's disease. Neurology 2001, 57:658-662.
23. Sanchez-Pernaute R, Kunig G, del Barrio AA, de Yebenes JG, Vontobel P, Leenders KL. Bradykinesia in early Huntington's disease. Neurology 2000, 54:119-125.
24. Squitieri F. Berardelli A Nargi E, Castellotti B, Mariotti C, Cannella M, et al.: Atypical movement disorders in the early stages of Huntington's disease: clinical and genetic analysis. Clin Genet 2000, 58:50-56.
25. Schwarcz R, Bernnett JP Jr, Coyle JT: Inhibitors of GABA metabolism: implications for Huntington's disease. Ann Neurol 1977, 2:299-303.
26. Caviness JN, Kurth M: Cortical Myoclonus in Huntington's disease associated with an enlarged somatosensory evoked potential. Mov Disord 1997, 12:1046-51.
27. Lagace DC, Eisch AJ: Mood-stabilizing drugs: are their neuroprotective aspects clinically relevant? Psychiatr Clin North Am 2005, 28:399-414.
28. Peng GS, Li G, Tzeng NS, Chen PS, Chuang DM, Hsu YD, Yang S, Hong JS: Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia. Brain Res Mol Brain Res 2005, 24(134):162-9.
29. Chuang DM: Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases? Crit Rev Neurobiol 2004, 16:83-90.
30. Sugai F, Yamamoto Y, Miyaguchi K, Zhou Z, Sumi H, Hamasaki T, Goto M, Sakoda S: Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur J Neurosci 2004, 20:3179-83.
31. Morland C, Boldingh KA, Iversen EG, Hassel B: Valproate is neuroprotective against malonate toxicity in rat striatum: an association with augmentation of high-affinity glutamate uptake. J Cereb Blood Flow Metab 2004, 24:1226-34.
32. Kanai H, Sawa A, Chen RW, Leeds P, Chuang DM: Valproic acid inhibits histone deacetylase activity and suppresses excitotoxicity-induced GAPDH nuclear accumulation and apoptotic death in neurons. Pharmacogenomics J 2004, 4:336-44.
33. Jeong MR, Hashimoto R, Senatorov W, Fujimaki K, Ren M, Lee MS, Chuang DM: Valproic acid, a mood stabilizer and anticonvulsant, protects rat cerebral cortical neurons from spontaneous cell death: a role of histone deacetylase inhibition. FEBS Lett 2003, 542:74-8.
34. Wang JF, Azzam JE, Young LT. Valproate inhibits oxidative damage to lipid and protein in primary cultured rat cerebrocortical cells. Neuroscience 2003, 116:485-9.
35. Loy R, Tariot PN: Neuroprotective properties of valproate: potential benefit for AD and taucipathies. J Mol Neurosci 2002, 19:303-7.
36. Vajda FJ: Valproate and neuroprotection. J Clin Neurosci 2002, 9:508-14.